Berotralstat (Orladeyo) for prophylaxis of hereditary angioedema
Defines medical necessity and prior-authorization criteria for berotralstat (Orladeyo) for prevention of hereditary angioedema (HAE) attacks in eligible members aged 12 and older; applies to commercial and Medicaid lines of business except California Exchange Plans.
No material clinical or coverage changes in this revision.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.